Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 10/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 4/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622678 | 0.84 | KHK (0.48) | NOTUMGAAKDM4EDPP4DPP8 | |
| SCHEMBL2557573 | 0.83 | KDM4E (0.67) | NOTUMGAAKDM4EDPP4DPP9 | |
| SCHEMBL5799674 | 0.83 | NOTUM (0.65) | NOTUMSERPINE1 | |
| SCHEMBL29954991 | 0.83 | NOTUM (0.65) | NOTUMSERPINE1 | |
| SCHEMBL2558768 | 0.82 | GAA (0.78) | NOTUMGAAKDM4ECYP2C19 | |
| Trifluoroacetic Acid SCHEMBL4359200 | 0.82 | FFAR4 (0.47) | NOTUMGAAKDM4EDPP4DPP8 | |
| SCHEMBL2555803 | 0.81 | GAA (0.57) | NOTUMGAAKDM4ECYP2C19 | |
| SCHEMBL16792970 | 0.78 | KDM4E (0.58) | GAAKDM4EDPP4DPP8DPP9 | |
| SCHEMBL4359206 | 0.77 | DPP4 (0.43) | NOTUMGAAKDM4ETNKSTNKS2 | |
| SCHEMBL3089450 | 0.76 | EPHX2 (0.51) | KDM4ECYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | claimed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | claimed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | NOTUM 3548/4885GAA 4677/4885KDM4E 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.